796071-90-4

Usage

Uses

Used in Medicinal Chemistry:
(5-FLUOROINDOL-1-YL)ACETIC ACID is used as a chemical compound for its potential to modify biological systems through interactions with receptors and enzymes. Its unique structure allows it to be a promising candidate in the development of new drugs and therapies.
Used in Pharmaceutical Research:
(5-FLUOROINDOL-1-YL)ACETIC ACID is used as a research tool for studying the effects of indole derivatives on biological systems. Its ability to interact with receptors and enzymes makes it a valuable asset in understanding the mechanisms of action and potential therapeutic applications of related compounds.
Used in Organic Synthesis:
(5-FLUOROINDOL-1-YL)ACETIC ACID is used as a building block in the synthesis of more complex organic molecules. Its unique structure and functional groups make it a versatile component in the creation of new compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C10H8FNO2/c11-8-1-2-9-7(5-8)3-4-12(9)6-10(13)14/h1-5H,6H2,(H,13,14)

Upstream product

• 1344079-83-9 2-(5-fluoro-1H-indol-1-yl)acetonitrile 
• 1343059-96-0 C₁₁H₁₀FNO₂ 
• 399-52-0 5-fluoro-1H-indole 
• 1340128-44-0 ethyl 2-(5-fluoro-1H-indol-1-yl)acetate 

Relevant academic research and scientific papers

CHEMICAL SUBSTANCES WHICH INHIBIT THE ENZYMATIC ACTIVITY OF HUMAN KALLIKREIN-RELATED PEPTIDASE 6 (KLK6)

The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein-like peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds or pharmaceutical compositions.

Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure-Activity Relationships and Membrane Targeting Properties

Antibacterials that disrupt cell membrane function have the potential to eradicate “persister” organisms and delay the emergence of resistance. Here we report the antimycobacterial activities of 4-fluoro and 6-methoxyindoles bearing a cationic amphiphilic motif represented by a lipophilic n-octyl side chain at position 1 and a positively charged azepanyl or 1,4-dioxa-8-azaspiro[4.5]decane moiety at position 3. These analogues exhibited balanced profiles of potency (Mycobacterium bovis BCG, M tuberculosis H37Rv), selective activity, solubility, and metabolic stability. Bacteriological mechanism of action investigations on a representative analogue revealed cell membrane permeabilization and depolarization in M bovis BCG. These membrane-related changes preceded cell death indicating that the loss in membrane integrity was not an epiphenomenon. Bactericidal activity was observed against both growing and nongrowing mycobacterial cultures. The analogue also upregulated cell envelope stress-inducible promoters piniBAC and pclgR, implicating the involvement of envelope-related targets in its mode of action.

Indolyl and dihydroindolyl N-glycinamides as potent and in vivo active NPY5 antagonists

A novel series of indolyl and dihydroindolyl glycinamides were identified as potent NPY5 antagonists with in vivo activity from screen hit 1. The dihydroindolyl glycinamide 10a significantly inhibits NPY5 agonist induced feeding at a dose of 0.1 mg/kg. The indolyl glycinamide 12c also inhibits NPY5 agonist induced feeding at a dose of 1 mg/kg. Both compounds 10a and 12c represent potential tools for further investigation into the biology of the NPY5 receptor.

Synthesis and evaluation of indole aspartyl ketones as novel caspase-3 inhibitors

Synthesis, biological evaluation and structure-activity relationships for a series of novel nonpeptide small molecule inhibitors of caspase-3 are described. Among the synthesized compounds, 2,3,5,6-tetrafluorophenoxymethyl ketone derivatives of indole-N-a

SUBSTITUTED AMINO CARBOXYLIC ACIDS

Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.